-
- 抗原 See all IFITM1 抗体
- IFITM1 (Interferon-Induced Transmembrane Protein 1 (IFITM1))
-
抗原表位
- C-Term
-
适用
- 人
-
宿主
- 兔
-
克隆类型
- 多克隆
-
标记
- This IFITM1 antibody is un-conjugated
-
应用范围
- Western Blotting (WB), Immunohistochemistry (IHC)
- 序列
- CCLGFIAFAY SVKSRDRKMV GDVTGAQAYA STAKCLNIWA LILGILMTIG FILLLVFGSV TVYHIMLQII QEKRGY
- 交叉反应
- 人, 小鼠
- 产品特性
- Polyclonal Antibodies
- 纯化方法
- Affinity purification
- 免疫原
- A synthetic peptide corresponding to a sequence within amino acids 50 to the C-terminus of human IFITM1 (NP_003632.3).
- 亚型
- IgG
-
-
- 应用备注
- WB,1:200 - 1:2000,IHC,1:50 - 1:200
- 限制
- 仅限研究用
-
- 缓冲液
- PBS with 0.02 % sodium azide,50 % glycerol, pH 7.3.
- 储存液
- Sodium azide
- 注意事项
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- 储存条件
- -20 °C
- 储存方法
- Store at -20°C. Avoid freeze / thaw cycles.
-
-
CRISPR/Cas9-mediated deletion of miR-146a enhances antiviral response in HIV-1 infected cells." in: Genes and immunity, (2018) (PubMed).
: "
-
CRISPR/Cas9-mediated deletion of miR-146a enhances antiviral response in HIV-1 infected cells." in: Genes and immunity, (2018) (PubMed).
-
- 抗原
- IFITM1 (Interferon-Induced Transmembrane Protein 1 (IFITM1))
- 别名
- IFITM1 (IFITM1 产品)
- 别名
- 9-27 antibody, CD225 antibody, DSPA2a antibody, IFI17 antibody, LEU13 antibody, 1110036C17Rik antibody, Mil-2 antibody, Mil2 antibody, interferon induced transmembrane protein 1 antibody, interferon induced transmembrane protein 1 (9-27) antibody, Ifitm1 antibody, IFITM1 antibody
- 背景
- IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol. Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2, Marburg virus (MARV, Ebola virus (EBOV, Dengue virus (DNV, West Nile virus (WNV, human immunodeficiency virus type 1 (HIV-1 and hepatitis C virus (HCV. Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2-mediated viral entry and SARS-CoV and SARS-CoV-2 S protein-mediated viral entry. Also implicated in cell adhesion and control of cell growth and migration. Inhibits SARS-CoV-2 S protein-mediated syncytia formation. Plays a key role in the antiproliferative action of IFN-gamma either by inhibiting the ERK activation or by arresting cell growth in G1 phase in a p53-dependent manner. Acts as a positive regulator of osteoblast differentiation. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation. IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome.,IFITM1,9-27,CD225,DSPA2a,IFI17,LEU13,Cancer,Tumor biomarkers,Tumor suppressors,p53 pathway,Signal Transduction,Immunology & Inflammation,CD markers,Cytokines,Interferons,Cell Intrinsic Innate Immunity Signaling Pathway,Stem Cells,IFITM1
- 分子量
- 13 kDa
- 基因ID
- 8519
- UniProt
- P13164
-